2. Academic Validation
  3. Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73

Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73

  • J Med Chem. 2024 Jun 13;67(11):9686-9708. doi: 10.1021/acs.jmedchem.4c00825.
Cunjian Shi 1,  Longfeng Chang 1,  Jie Wang 1,  Jingqi Dai 1,  Wenyue Xu 1,  Jiangyang Tang 1,  Wenyi Mei 1,  Chen Zhang 1,  Zedong Wang 1,  Yichen Liao 1,  Xingsen Zhang 1,  Wenzhe Jiang 1,  Guozhen Zhang 1,  Zhenjiang Zhao 1,  Yufang Xu 1,  Lili Zhu 1,  Honglin Li 1 2 3
Affiliations

Affiliations

  • 1 Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
  • 2 Innovation Center for AI and Drug Discovery, East China Normal University, Shanghai 200062, China.
  • 3 Lingang Laboratory, Shanghai 200031, China.
PMID: 38809692 DOI: 10.1021/acs.jmedchem.4c00825
Abstract

High extracellular concentrations of adenosine triphosphate (ATP) in the tumor microenvironment generate adenosine by sequential dephosphorylation of CD39 and CD73, resulting in potent immunosuppression to inhibit T cell and natural killer (NK) cell function. CD73, as the determining Enzyme for adenosine production, has been shown to correlate with poor clinical tumor prognosis. Conventional inhibitors as analogues of adenosine 5'-monophosphate (AMP) may have a risk of further metabolism to adenosine analogues. Here, we report a new series of malonic acid non-nucleoside inhibitors coordinating with zinc ions of CD73. Compound 12f was found to be a superior CD73 Inhibitor (IC50 = 60 nM) by structural optimization, and its pharmacokinetic properties were investigated. In mouse tumor models, compound 12f showed excellent efficacy and reversal of immunosuppression in combination with chemotherapeutic agents or checkpoint inhibitors, suggesting that it deserves further development as a novel CD73 Inhibitor.

Figures
Products